Galapagos NV Company Profile (NASDAQ:GLPG)

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos NV is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Galapagos NV.

9 brokers have issued 1 year price objectives for Galapagos NV's shares. Their predictions range from $98.00 to $124.00. On average, they anticipate Galapagos NV's stock price to reach $111.83 in the next year. View Analyst Ratings for Galapagos NV.

Here are some recent quotes from research analysts about Galapagos NV stock:

• 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (10/11/2017)
• 2. Stifel Nicolaus analysts commented, "Aurinia reported 2Q17 financial results in an after market close press release." (8/11/2017)
• 3. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)
• 4. Cowen and Company analysts commented, "GLPG provided a broad pipeline update at an R&D day." (6/21/2017)
• 5. Instinet analysts commented, "We are initiating coverage on Galapagos (GLPG) with a buy rating and $87 target price. We believe the company's rapidly advancing cystic fibrosis (CF) pipeline, partnered with AbbVie, will drive shares higher in the next 12 months. We also anticipate an increasing focus on filgotinib's opportunity in Crohn's disease, and ulcerative colitis (UC) in Phase 3 trials, may lead to upside in shares over the next 12-months. In our view, the current valuation is predominantly supported primarily by the blockbuster opportunity for the company's lead oral JAK1 inhibitor, filgotinib (partnered with Gilead), for the treatment of rheumatoid arthritis." (3/1/2017)

Galapagos NV saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 403,300 shares, a drop of 27.4% from the August 31st total of 555,345 shares. Based on an average trading volume of 105,234 shares, the short-interest ratio is currently 3.8 days.

Some companies that are related to Galapagos NV include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), FibroGen (FGEN) and Nektar Therapeutics (NKTR).

Galapagos NV's management team includes the folowing people:

• Onno van de Stolpe, Chief Executive Officer, Executive Director
• Bart Filius, Chief Financial Officer
• Andre Hoekema, Senior Vice President - Corporate Development
• Piet Wigerinck, Chief Scientific Officer
• Rajesh Parekh, Non-Executive Chairman of the Board
• Harrold van Barlingen, Non-Executive Director
• Katrine Bosley, Independent Non-Executive Director
• Werner Cautreels, Non-Executive Independent Director
• Christine Mummery, Non-Executive Independent Director

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos NV's stock is owned by a number of of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.00%). View Institutional Ownership Trends for Galapagos NV.

Galapagos NV's stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Galapagos NV.

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Galapagos NV stock can currently be purchased for approximately $101.66.